Cite
HARVARD Citation
Iannazzo, S. et al. (2013). Individualized Treatment of Hbeag-Negative Chronic Hepatitis B Using Pegylated Interferon-α2A as First-Line and Week-12 HBV Dna/Hbsag Stopping Rule: A Cost-Effectiveness Analysis. Antiviral therapy. 18 (4), pp. 1-11. [Online].